stockportfolio.pro
QuidelOrtho Corporation (QDEL)
Healthcare · Medical Devices · NasdaqGS
QuidelOrtho Corporation revenue & earnings — last 6 fiscal years
| Metric | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.66B | $1.70B | $3.27B | $3.00B | $2.78B | $2.73B |
| Gross profit | — | — | — | — | — | — |
| Net income | $810.30M | $704.20M | $548.70M | $-10.10M | $-2.03B | $-1.13B |
| Net margin | 48.8% | 41.5% | 16.8% | -0.3% | -72.8% | -41.5% |
Source: QuidelOrtho Corporation SEC filings (10-K).
Explore 6 years of QuidelOrtho Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track QDEL in your portfolio →
About QuidelOrtho Corporation
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
QuidelOrtho Corporation — frequently asked questions
What is QuidelOrtho Corporation's revenue?
QuidelOrtho Corporation (QDEL) reported revenue of $2.73B for fiscal year 2025, down 1.9% from the prior year, according to its SEC filings.
Is QuidelOrtho Corporation profitable?
No — QDEL reported a net loss of $-1.13B in fiscal 2025.
What is QDEL's P/E ratio?
QuidelOrtho Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is QuidelOrtho Corporation growing?
QDEL's revenue grew at roughly 10.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from QuidelOrtho Corporation's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.